Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Renal Cell 26Sarcoma 16Neoplasm Metastasis 12Carcinoma, Non-Small-Cell Lung 9Ovarian Neoplasms 8Breast Neoplasms 8Recurrence 6Neoplasms 5Melanoma 4Liposarcoma 4Leiomyosarcoma 4Glioblastoma 4Fallopian Tube Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Neuroendocrine Tumors 3Lung Neoplasms 3Kidney Neoplasms 3Hemangiosarcoma 3Gastrointestinal Stromal Tumors 3Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Sarcoma, Synovial 2Sarcoma, Alveolar Soft Part 2Rhabdomyosarcoma 2Pancreatic Neoplasms 2Osteosarcoma 2Gliosarcoma 2

Interventions

pazopanib 1YF 476 1Temozolomide 1Streptozocin 1Pantoprazole 1Omeprazole 1Interferons 1Fluorouracil 1Doxorubicin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Zollinger-Ellison Syndrome × pazopanib × Clear all
NCT00454363 2020-04-03

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled 11 charts
Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Zollinger-Ellison Syndrome, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡